[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"toqa saad mohammed mohammed\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100581910","phase-1-the-role-of-coenzyme-q10-in-the-prophylaxis-of-oxaliplatin-induced-peripheral-neuropathy-in-patients-with-colorectal-cancer-100581910",false,"NCT06856447","The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer","Inclusion Criteria:\n\n* Patients with histologically confirmed diagnosis of Stage III colorectal cancer.\n* Patients who will be scheduled to receive modified FOLFOX-6.\n* Patients with no contraindication to chemotherapy.\n* Males and females aged ≥ 18 years old.\n* Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5 × 109 \u002FL, platelet count ≥ 100 × 109 \u002FL and hemoglobin level ≥ 10 g\u002Fdl).\n* Patients with adequate renal function (serum creatinine \\\u003C 1.5 mg\u002Fdl\n* Patients with adequate liver function (serum bilirubin \\\u003C 1.2 mg\u002Fdl).\n* Patients with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG) score.\n* Patients who may receive medications to counteract chemotherapy induced neuropathic pain (gabapentin, lamotrigine, carbamazepine, etc….).\n\nExclusion Criteria:\n\n* Exclusion criteria\n\n  * Patients with prior exposure to neurotoxic agents (Cisplatin, vincristine, paclitaxel, docetaxol, foscarnet, INH, etc..) in the last 6 months.\n  * Patients with evidence of metastasis at the initial assessment.\n  * Concomitant use of antioxidant vitamins (vitamin A, C, E),\n  * Preexisting peripheral neuropathy resulting from other causes such as diabetes and brain disorders, hypothyroidism, autoimmune diseases, hepatitis C.\n  * Patients with diabetes.\n  * Patients with inflammatory diseases (ulcerative colitis, rheumatoid arthritis).\n  * Patients with stressful conditions as smoking, COPD, ….\n  * Patients with active liver disease (cirrhosis, fatty liver, hepatitis C, etc..).\n  * Patients with myopathy\n  * Patients with renal impairment, including those with end-stage renal disease and those receiving dialysis.\n  * Pregnant and breast feeding women.\n  * Concurrent use of diltiazem, metoprolol, enalapril, nitroglycerin, warfarin, clopidigrel, aspirin, statins, fibrates, tricyclic antidepressant medications,",true,"ALL","18 Years",{"count":19,"type":20},22,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This study aims to evaluate the possible beneficial role of coenzyme Q10 against oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.",[26],"Colorectal Cancer",[28,29,30,31],"Oxaliplatin-induced neuropathy","Coenzyme Q10","Neuroprotection in cancer","Chemotherapy-induced neuropathy","RECRUITING","2025-02-26",{"date":35,"type":36},"2025-03-04","ACTUAL",{"date":38,"type":36},"2024-06-01",{"date":40,"type":20},"2026-01-10",{"name":42,"class":43},"toqa saad mohammed mohammed","OTHER",""]